Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
PGP9.5
Parkinson's disease
RBD
UCHL1
alpha-synuclein
skin biopsy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
27
10
2020
received:
05
08
2020
accepted:
29
10
2020
pubmed:
25
11
2020
medline:
20
5
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Recent studies reported abnormal alpha-synuclein deposition in biopsy-accessible sites of the peripheral nervous system in Parkinson's disease (PD). This has considerable implications for clinical diagnosis. Moreover, if deposition occurs early, it may enable tissue diagnosis of prodromal PD. The aim of this study was to develop and test an automated bright-field immunohistochemical assay of cutaneous pathological alpha-synuclein deposition in patients with idiopathic rapid eye movement sleep behavior disorder, PD, and atypical parkinsonism and in control subjects. For assay development, postmortem skin biopsies were taken from 28 patients with autopsy-confirmed Lewy body disease and 23 control subjects. Biopsies were stained for pathological alpha-synuclein in automated stainers using a novel dual-immunohistochemical assay for serine 129-phosphorylated alpha-synuclein and pan-neuronal marker protein gene product 9.5. After validation, single 3-mm punch skin biopsies were taken from the cervical 8 paravertebral area from 79 subjects (28 idiopathic rapid eye movement sleep behavior disorder, 20 PD, 10 atypical parkinsonism, and 21 control subjects). Raters blinded to clinical diagnosis assessed the biopsies. The immunohistochemistry assay differentiated alpha-synuclein pathology from nonpathological-appearing alpha-synuclein using combined phosphatase and protease treatments. Among autopsy samples, 26 of 28 Lewy body samples and none of the 23 controls were positive. Among living subjects, punch biopsies were positive in 23 (82%) subjects with idiopathic rapid eye movement sleep behavior disorder, 14 (70%) subjects with PD, 2 (20%) subjects with atypical parkinsonism, and none (0%) of the control subjects. After a 3-year follow-up, eight idiopathic rapid eye movement sleep behavior disorder subjects phenoconverted to defined neurodegenerative syndromes, in accordance with baseline biopsy results. Even with a single 3-mm punch biopsy, there is considerable promise for using pathological alpha-synuclein deposition in skin to diagnose both clinical and prodromal PD. © 2020 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Recent studies reported abnormal alpha-synuclein deposition in biopsy-accessible sites of the peripheral nervous system in Parkinson's disease (PD). This has considerable implications for clinical diagnosis. Moreover, if deposition occurs early, it may enable tissue diagnosis of prodromal PD.
OBJECTIVE
The aim of this study was to develop and test an automated bright-field immunohistochemical assay of cutaneous pathological alpha-synuclein deposition in patients with idiopathic rapid eye movement sleep behavior disorder, PD, and atypical parkinsonism and in control subjects.
METHODS
For assay development, postmortem skin biopsies were taken from 28 patients with autopsy-confirmed Lewy body disease and 23 control subjects. Biopsies were stained for pathological alpha-synuclein in automated stainers using a novel dual-immunohistochemical assay for serine 129-phosphorylated alpha-synuclein and pan-neuronal marker protein gene product 9.5. After validation, single 3-mm punch skin biopsies were taken from the cervical 8 paravertebral area from 79 subjects (28 idiopathic rapid eye movement sleep behavior disorder, 20 PD, 10 atypical parkinsonism, and 21 control subjects). Raters blinded to clinical diagnosis assessed the biopsies.
RESULTS
The immunohistochemistry assay differentiated alpha-synuclein pathology from nonpathological-appearing alpha-synuclein using combined phosphatase and protease treatments. Among autopsy samples, 26 of 28 Lewy body samples and none of the 23 controls were positive. Among living subjects, punch biopsies were positive in 23 (82%) subjects with idiopathic rapid eye movement sleep behavior disorder, 14 (70%) subjects with PD, 2 (20%) subjects with atypical parkinsonism, and none (0%) of the control subjects. After a 3-year follow-up, eight idiopathic rapid eye movement sleep behavior disorder subjects phenoconverted to defined neurodegenerative syndromes, in accordance with baseline biopsy results.
CONCLUSION
Even with a single 3-mm punch biopsy, there is considerable promise for using pathological alpha-synuclein deposition in skin to diagnose both clinical and prodromal PD. © 2020 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 33232556
doi: 10.1002/mds.28399
pmc: PMC10123546
mid: NIHMS1876686
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-904Subventions
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : NINDS NIH HHS
ID : U24 NS072026
Pays : United States
Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Neurology. 2014 Jul 29;83(5):406-12
pubmed: 24975862
J Neuropathol Exp Neurol. 2018 Oct 1;77(10):942-949
pubmed: 30137426
Neurochem Int. 2012 Nov;61(6):899-906
pubmed: 22342821
Mov Disord. 2015 Oct;30(12):1688-92
pubmed: 26175301
Acta Neuropathol. 2017 Apr;133(4):535-545
pubmed: 28180961
Brain Sci. 2016 May 26;6(2):
pubmed: 27240409
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Neurology. 2013 Oct 29;81(18):1604-10
pubmed: 24089386
Acta Neuropathol. 2014 Jul;128(1):99-109
pubmed: 24788821
Front Genet. 2014 Nov 07;5:382
pubmed: 25426138
J Neuropathol Exp Neurol. 2008 May;67(5):402-16
pubmed: 18451726
Mov Disord. 2013 May;28(5):597-604
pubmed: 23554107
Mov Disord. 2004 Nov;19(11):1306-12
pubmed: 15390007
J Neurosci. 2011 May 11;31(19):6963-71
pubmed: 21562258
Neurology. 2016 Aug 2;87(5):505-12
pubmed: 27385742
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neuropathology. 2015 Aug;35(4):354-89
pubmed: 25619230
J Parkinsons Dis. 2016;6(1):153-63
pubmed: 26756744
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Parkinsonism Relat Disord. 2010 May;16(4):252-5
pubmed: 20097595
Neurology. 2008 May 13;70(20):1916-25
pubmed: 18474848
J Neuropathol Exp Neurol. 2006 Apr;65(4):387-95
pubmed: 16691119
Ann Neurol. 2015 May;77(5):830-9
pubmed: 25767079
Mov Disord. 2018 Oct;33(10):1551-1554
pubmed: 30288780
PLoS One. 2014 Feb 26;9(2):e89741
pubmed: 24587002
Neurology. 2017 Aug 22;89(8):776-784
pubmed: 28747449
J Clin Invest. 2002 Nov;110(10):1403-5
pubmed: 12438436
Brain. 2015 Aug;138(Pt 8):2310-21
pubmed: 26017579
Neurology. 2017 May 30;88(22):2128-2131
pubmed: 28468843
Eur J Biochem. 1995 Jan 15;227(1-2):367-71
pubmed: 7851410
Neurology. 2014 Apr 15;82(15):1362-9
pubmed: 24634456
Brain. 2017 Jul 1;140(7):1959-1976
pubmed: 28549077
J Neurosci. 2015 Oct 14;35(41):13853-9
pubmed: 26468185
Brain. 2008 Mar;131(Pt 3):642-50
pubmed: 18079166
Mol Neurobiol. 2013 Apr;47(2):552-60
pubmed: 22923346
Mov Disord. 2015 Sep;30(10):1413-7
pubmed: 26265105
Mov Disord. 2012 Jun;27(7):831-42
pubmed: 22451330
JAMA Neurol. 2015 Aug;72(8):863-73
pubmed: 26076039
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229